Now showing items 1-20 of 3706

    • Pan-cancer analysis of whole genomes. 

      ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium (2020-02-05)
      Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1-3. Here we report the integrative analysis of ...
    • Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. 

      Yang, X; Song, H; Leslie, G; Engel, C; Hahnen, E; Auber, B; Horváth, J; Kast, K; Niederacher, D; Turnbull, C; Houlston, R; Hanson, H; Loveday, C; Dolinsky, JS; LaDuca, H; Ramus, SJ; Menon, U; Rosenthal, AN; Jacobs, I; Gayther, SA; Dicks, E; Nevanlinna, H; Aittomäki, K; Pelttari, LM; Ehrencrona, H; Borg, Å; Kvist, A; Rivera, B; Hansen, TVO; Djursby, M; Lee, A; Dennis, J; Bowtell, DD; Traficante, N; Diez, O; Balmaña, J; Gruber, SB; Chenevix-Trench, G; kConFab Investigators; Jensen, A; Kjær, SK; Høgdall, E; Castéra, L; Garber, J; Janavicius, R; Osorio, A; Golmard, L; Vega, A; Couch, FJ; Robson, M; Gronwald, J; Domchek, SM; Culver, JO; de la Hoya, M; Easton, DF; Foulkes, WD; Tischkowitz, M; Meindl, A; Schmutzler, RK; Pharoah, PDP; Antoniou, AC (2020-02-28)
      BACKGROUND:The purpose of this study was to estimate precise age-specific tubo-ovarian carcinoma (TOC) and breast cancer (BC) risks for carriers of pathogenic variants in RAD51C and RAD51D. METHODS:We analysed data from ...
    • Prostate-Specific Membrane Antigen expression in melanoma metastases. 

      Snow, H; Hazell, S; Francis, N; Mohammed, K; O'Neill, S; Davies, E; Mansfield, D; Messiou, C; Hujairi, N; Nicol, D; Harrington, K; Smith, M (2020-06-11)
      BACKGROUND:Prostate-specific membrane antigen (PSMA) is a prostatic epithelial protein that is used as a radiotracer (68Ga-PSMA-11) for prostate cancer staging. PSMA-PET/CT performed for prostate cancer has been observed ...
    • Impact of mitochondrial DNA mutations in multiple myeloma. 

      Hoang, PH; Cornish, AJ; Chubb, D; Jackson, G; Kaiser, M; Houlston, RS
    • Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? 

      Cojocaru, E; Wilding, C; Engelman, B; Huang, P; Jones, RL (Springer Science and Business Media LLC, 2020-03)
    • CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo. 

      Alajati, A; D'Ambrosio, M; Troiani, M; Mosole, S; Pellegrini, L; Chen, J; Revandkar, A; Bolis, M; Theurillat, J-P; Guccini, I; Losa, M; Calcinotto, A; De Bernardis, G; Pasquini, E; D'Antuono, R; Sharp, A; Figueiredo, I; Nava Rodrigues, D; Welti, J; Gil, V; Yuan, W; Vlajnic, T; Bubendorf, L; Chiorino, G; Gnetti, L; Torrano, V; Carracedo, A; Camplese, L; Hirabayashi, S; Canato, E; Pasut, G; Montopoli, M; Rüschoff, JH; Wild, P; Moch, H; De Bono, J; Alimonti, A (2020-05)
      The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to lethal castration-resistant prostate cancer (CRPC) are poorly understood. Identification of clinically relevant genetic ...
    • Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models. 

      Zenke, FT; Zimmermann, A; Sirrenberg, C; Dahmen, H; Kirkin, V; Pehl, U; Grombacher, T; Wilm, C; Fuchss, T; Amendt, C; Vassilev, LT; Blaukat, A
      Physical and chemical DNA-damaging agents are used widely in the treatment of cancer. Double-strand break (DSB) lesions in DNA are the most deleterious form of damage and, if left unrepaired, can effectively kill cancer ...
    • Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. 

      Murray Brunt, A; Haviland, JS; Wheatley, DA; Sydenham, MA; Alhasso, A; Bloomfield, DJ; Chan, C; Churn, M; Cleator, S; Coles, CE; Goodman, A; Harnett, A; Hopwood, P; Kirby, AM; Kirwan, CC; Morris, C; Nabi, Z; Sawyer, E; Somaiah, N; Stones, L; Syndikus, I; Bliss, JM; Yarnold, JR; FAST-Forward Trial Management Group
      BACKGROUND:We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard ...
    • Inhibitors in AKTion: ATP-competitive vs allosteric. 

      Lazaro, G; Kostaras, E; Vivanco, I (2020-06)
      Aberrant activation of the PI3K pathway is one of the commonest oncogenic events in human cancer. AKT is a key mediator of PI3K oncogenic function, and thus has been intensely pursued as a therapeutic target. Multiple AKT ...
    • Olaparib for Metastatic Castration-Resistant Prostate Cancer. 

      de Bono, J; Mateo, J; Fizazi, K; Saad, F; Shore, N; Sandhu, S; Chi, KN; Sartor, O; Agarwal, N; Olmos, D; Thiery-Vuillemin, A; Twardowski, P; Mehra, N; Goessl, C; Kang, J; Burgents, J; Wu, W; Kohlmann, A; Adelman, CA; Hussain, M (2020-05-28)
      BACKGROUND:Multiple loss-of-function alterations in genes that are involved in DNA repair, including homologous recombination repair, are associated with response to poly(adenosine diphosphate-ribose) polymerase (PARP) ...
    • Edge effects in 3D dosimetry: characterisation and correction of the non-uniform dose response of PRESAGE®. 

      Costa, F; Doran, SJ; Hanson, IM; Adamovics, J; Nill, S; Oelfke, U (2020-05)
      Previous work has shown that PRESAGE® can be used successfully to perform 3D dosimetric measurements of complex radiotherapy treatments. However, measurements near the sample edges are known to be difficult to achieve. ...
    • A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. 

      Jones, R; Crabb, S; Chester, J; Elliott, T; Huddart, R; Birtle, A; Evans, L; Lester, J; Jagdev, S; Casbard, A; Huang, C; Madden, T-A; Griffiths, G (2020-04-25)
      OBJECTIVES:To assess the efficacy and tolerability of the dual epidermal growth factor receptor/vascular endothelial growth factor receptor inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the ...
    • Search for multiple myeloma risk factors using Mendelian randomization. 

      Went, M; Cornish, AJ; Law, PJ; Kinnersley, B; van Duin, M; Weinhold, N; Försti, A; Hansson, M; Sonneveld, P; Goldschmidt, H; Morgan, GJ; Hemminki, K; Nilsson, B; Kaiser, M; Houlston, RS (2020-05)
      The etiology of multiple myeloma (MM) is poorly understood. Summary data from genome-wide association studies (GWASs) of multiple phenotypes can be exploited in a Mendelian randomization (MR) phenome-wide association study ...
    • Prognostic gene expression signature for high-grade serous ovarian cancer. 

      Millstein, J; Budden, T; Goode, EL; Anglesio, MS; Talhouk, A; Intermaggio, MP; Leong, HS; Chen, S; Elatre, W; Gilks, B; Nazeran, T; Volchek, M; Bentley, RC; Wang, C; Chiu, DS; Kommoss, S; Leung, SCY; Senz, J; Lum, A; Chow, V; Sudderuddin, H; Mackenzie, R; George, J; AOCS Group; Fereday, S; Hendley, J; Traficante, N; Steed, H; Koziak, JM; Köbel, M; McNeish, IA; Goranova, T; Ennis, D; Macintyre, G; Silva, D; Ramón Y Cajal, T; García-Donas, J; Polo, SH; Rodriguez, GC; Cushing-Haugen, KL; Harris, HR; Greene, CS; Zelaya, RA; Behrens, S; Fortner, RT; Sinn, P; Herpel, E; Lester, J; Lubiński, J; Oszurek, O; Tołoczko, A; Cybulski, C; Menkiszak, J; Pearce, CL; Pike, MC; Tseng, C; Alsop, J; Rhenius, V; Song, H; Jimenez-Linan, M; Piskorz, A; Gentry-Maharaj, A; Karpinskyj, C; Widschwendter, M; Singh, N; Kennedy, CJ; Sharma, R; Harnett, PR; Gao, B; Johnatty, SE; Sayer, R; Boros, J; Winham, SJ; Keeney, GL; Kaufmann, SH; Larson, MC; Luk, H; Hernandez, BY; Thompson, PJ; Wilkens, LR; Carney, ME; Trabert, B; Lissowska, J; Brinton, L; Sherman, ME; Bodelon, C; Hinsley, S; Lewsley, LA; Glasspool, R; Banerjee, SN; Stronach, EA; Haluska, P; Ray-Coquard, I; Mahner, S; Winterhoff, B; Slamon, D; Levine, DA; Kelemen, LE; Benitez, J; Chang-Claude, J; Gronwald, J; Wu, AH; Menon, U; Goodman, MT; Schildkraut, JM; Wentzensen, N; Brown, R; Berchuck, A; Chenevix-Trench, G; A deFazio; Gayther, SA; García, MJ; Henderson, M; Rossing, MA; Beeghly-Fadiel, A; Fasching, PA; Orsulic, S; Karlan, BY; Konecny, GE; Huntsman, DG; Bowtell, DD; Brenton, JD; Doherty, JA; Pharoah, PDP; Ramus, SJ (2020-05-27)
      BACKGROUND:Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is approximately four years, yet survival varies widely between patients. There are no well-established, gene expression ...
    • Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions. 

      Lord, CJ; Quinn, N; Ryan, CJ (2020-05-28)
      Genetic interactions, including synthetic lethal effects, can now be systematically identified in cancer cell lines using high-throughput genetic perturbation screens. Despite this advance, few genetic interactions have ...
    • High-throughput molecular cancer cell line characterization using digital multiplex ligation-dependent probe amplification for improved standardization of in vitro research 

      Menezes, K; Atanesyan, L; Sherborne, AL; Steenkamer, M; Clemens, I; Savola, S; Kaiser, MF (Elsevier BV, 2020-06)
    • Molecular mechanism of APC/C activation by mitotic phosphorylation. 

      Zhang, S; Chang, L; Alfieri, C; Zhang, Z; Yang, J; Maslen, S; Skehel, M; Barford, D (2016-05)
      In eukaryotes, the anaphase-promoting complex (APC/C, also known as the cyclosome) regulates the ubiquitin-dependent proteolysis of specific cell-cycle proteins to coordinate chromosome segregation in mitosis and entry ...
    • Molecular basis of APC/C regulation by the spindle assembly checkpoint. 

      Alfieri, C; Chang, L; Zhang, Z; Yang, J; Maslen, S; Skehel, M; Barford, D (2016-08-10)
      In the dividing eukaryotic cell, the spindle assembly checkpoint (SAC) ensures that each daughter cell inherits an identical set of chromosomes. The SAC coordinates the correct attachment of sister chromatid kinetochores ...
    • A unique binding mode of Nek2A to the APC/C allows its ubiquitination during prometaphase. 

      Alfieri, C; Tischer, T; Barford, D (2020-06)
      The anaphase-promoting complex (APC/C) is the key E3 ubiquitin ligase which directs mitotic progression and exit by catalysing the sequential ubiquitination of specific substrates. The activity of the APC/C in mitosis is ...